Tempus Ai, Inc. · NASDAQ:TEM
Tempus Ai — Technical Presentation (September 2025)
12 slides from Tempus Ai's technical presentation, September 2025
Slide 1: Lower Checkpoint Gene Expression is Associated with Primary Resistance to Nivolumab-Ipilimumab in Advanced RCC
Lower Checkpoint Gene Expression is Associated with Primary Resistance to Nivolumab-Ipilimumab Combination in Advanced Renal Cell Carcinoma Rana R. McKay1, Adam J. Dugan2, Unnati Jariwala2, Karyn Ronski2, Jacob Mercer2, Eddy Saad3, Jad El Masri3, Marc Machaalani3, Mustafa Saleh3, Cody Rose4, Maxine
Slide 2: Background
Background • Immunotherapy combinations have emerged as the standard of care for patients with advanced RCC • Nivolumab-ipilimumab is associated with long-term durability, though a subset of patients do not derive any benefit from treatment CheckMate 214 CheckMate 214 rPFS (ITT) – Median Follow-Up 9
Slide 3: Rationale and Hypothesis
Rationale and Hypothesis Rationale: Urgent need to identify negative selection markers for treatment with nivolumab- ipilimumab Hypothesis: Molecular differences exist among tumors with and without primary progression to nivolumab-ipilimumab
Slide 4: Methods
Methods • Tempus Lens was used to select records for 106 patients with RCC who received 1L nivolumab-ipilimumab • Eligible patients: • Tumor samples collected within one year of treatment initiation • Processed using xT (DNA-seq) and xR (RNA-seq) assays • Treatment response: • Investigator-assessed
Slide 5: Baseline Characteristics
Baseline Characteristics PD (n=55) Non-PD (n=51) P-value Median or N (%) Median or N (%) Age at Diagnosis, years 59 58 0.962 Male 37 (67%) 40 (78%) 0.198 White 38 (83%) 37 (90%) 0.337 Hispanic/Latino 5 (15%) 7 (25%) 0.307 Current/Former Smoker 20 (36%) 21 (41%) 0.611 Prior nephrectomy 29 (53%) 24 (4
Slide 6: Specimen Source (N=106)
Specimen Source (N=106) 54% with matched normal DNA CNS=Central nervous system; GI=Gastrointestinal; PD=Progressive disease.
Slide 7: Checkpoint RNA Expression
Checkpoint RNA Expression * p<0.05, **p<0.01. CNS=Central nervous system; GI=Gastrointestinal; PD=Progressive disease.
Slide 8: Angiogenic Gene RNA Expression
Angiogenic Gene RNA Expression PD=Progressive disease.
Slide 9: Immune Cell Infiltrates
Immune Cell Infiltrates EXCLUSION ZONE ** p<0.01. Note – the following immune cell types had medians below 0 and were not included in this graph: Dendritic cells, monocytes, CD4 T cells. PD=Progressive disease.
Slide 10: Somatic Alterations
Somatic Alterations PD (n=55) Non-PD (n=51) P-value Q-value VHL, N (%) 34 (67%) 32 (58%) 0.368 0.9 PBRM1, N (%) 15 (29%) 16 (29%) 0.971 >0.9 SETD2, N (%) 8 (16%) 15 (27%) 0.148 0.9 TP53, N (%) 8 (16%) 14 (25%) 0.215 0.9 CDKN2A, N (%) 7 (14%) 11 (20%) 0.390 0.9 BAP1, N (%) 7 (14%) 6 (11%) 0.659 0.9 C
Slide 11: Conclusions
Conclusions EXCLUSION ZONE Primary resistant to This possibly nivolumab- reflects an Future prospective ipilimumab immune-cold studies, including characterized by microenvironment IHC validation, is lower RNA with limited T-cell warranted to confirm expression of infiltration and these findings immu
Slide 12: Acknowledgements
Acknowledgements • Patients and their families • Collaborating institutions • Tempus AI, Inc.